Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17765796 | MICROGLIA SPECIFIC PROMOTERS AND METHODS OF USE THEREFORE | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18011365 | NOVEL GAIN-OF-FUNCTION MUTANT OF BMPR2 GENE AND USE THEREOF | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18939375 | METHODS FOR COOLING AN ORGAN | Non-Final OA | Paragonix Technologies, Inc. |
| 17601581 | COMPOSITIONS AND METHODS FOR IN UTERO GENE EDITING FOR MONOGENIC LUNG DISEASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18892177 | METHODS FOR CREATING LINKAGE OF MULTIPLE VIRAL VECTORS FOR INTRACELLULAR DELIVERY | Final Rejection | Battelle Memorial Institute |
| 18029516 | BIOORTHOGONAL REPORTER GENE SYSTEM | Non-Final OA | Technische Universität München |
| 17564949 | Cell Culture System | Final Rejection | Saint-Gobain Performance Plastics Corporation |
| 17275084 | AUTOMATED GENERATION AND ANALYSIS OF ORGANOIDS | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 17287972 | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY | Final Rejection | Baylor College of Medicine |
| 17669874 | PANCREATIC DIFFERENTIATION | Final Rejection | Vertex Pharmaceuticals Incorporated |
| 18233146 | CELL EXPANSION SYSTEM | Non-Final OA | Terumo BCT, Inc. |
| 17982805 | PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR REPAIRING DAMAGED LIVER, TREATING DISEASE ASSOCIATED WITH DAMAGED LIVER AND IMPROVING FUNCTIONS OF LIVER | Final Rejection | TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD. |
| 18016251 | SONOGENETIC STIMULATION OF CELLS EXPRESSING TRPA1 | Non-Final OA | Salk Institute for Biological Studies |
| 18418855 | VECTOR FOR CANCER TREATMENT | Non-Final OA | CANCER RESEARCH TECHNOLOGY LIMITED |
| 17598814 | IMMUNODEFICIENT RODENT | Non-Final OA | CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS |
| 18161467 | CELLULAR REPROGRAMMING OF HUMAN ADIPOCYTES | Final Rejection | MIAMI UNIVERSITY |
| 17740665 | METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY | Non-Final OA | Legend Biotech USA Inc. |
| 17424140 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 17632026 | DUX4 EXPRESSING CELLS AND USES THEREOF | Final Rejection | Sana Biotechnology, Inc. |
| 18219649 | Engineered probiotic platform for in-situ conversion of sugars to functional ingredients | Non-Final OA | GutMind Corp |
| 17427720 | NEW USE OF STEM CELL GENERATOR IN PREPARATION OF BONE DEFECT REPAIR MATERIALS | Final Rejection | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY |
| 18168426 | COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 | Non-Final OA | Scribe Therapeutics Inc. |
| 18037986 | VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF | Non-Final OA | Umoja Biopharma, Inc. |
| 18034226 | AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMUNOTHERAPY OF CANCER | Non-Final OA | KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINKUM) |
| 18044560 | METHOD FOR OBTAINING PLATELET-DERIVED MITOCHONDRIA AND USE THEREOF | Non-Final OA | Paean Biotechnology Inc. |
| 18001306 | METHODS FOR PREPARATION OF IMMUNE CELLS | Final Rejection | ABELZETA INC. |
| 18172359 | RECOMBINANT BACULOVIRUSES, ALPHAVIRUS VIRUS-LIKE REPLICON PARTICLES PRODUCED THEREOF AND THEIR USES | Final Rejection | National Defense Medical University |
| 18005757 | METHODS AND COMPOSITIONS FOR TREATMENT OF FRAGILE X SYNDROME | Non-Final OA | FORGE BIOLOGICS, INC. |
| 18004975 | METHOD FOR TREATING ISCHEMIA CONDITION OF TISSUE | Final Rejection | WOEI-CHERNG SHYU |
| 17997680 | Methods For Treating Coronavirus Disease | Non-Final OA | Nisha Cell Therapeutics Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy